| Pipeline
On November 2, 2026, Ascletis Pharma announced two poster presentations at ObesityWeek in Washington, DC (November 14 to 17): ASC48, an oral GIP receptor agonist, and ASC37, an injected peptide that activates the GLP-1, GIP and glucagon receptors, the same three targets as retatrutide. The ASC37 poster title claims a half-life 6 times longer than retatrutide in monkeys and marked weight loss in obese mice. In earlier releases the company reported a half-life of about 17 days in monkeys against about 2.5 days for retatrutide, and, in an 11 day mouse study with daily dosing, a 14.1% weight change at 1 nmol/kg against 7.5% for tirzepatide. The company says the drug is designed for dosing once a month or less. No human data have been released. In July Ascletis said it planned to file with the FDA in the third quarter of 2026, and no filing has been announced.
Worth knowing: Every figure comes from company press releases, not a peer-reviewed paper. Half-lives in monkeys and weight loss in mice do not predict results in people; the reported half-life of retatrutide in people is about 6 days. ASC37 is not approved, has no registered human trial (a ClinicalTrials.gov search on November 2, 2026 found none) and is not available.
Related: Retatrutide | Drug pipeline
Source: Ascletis Pharma press releases: ObesityWeek posters, November 2, 2026 Company announcement, candidate selection, January 20, 2026 Company announcement and mouse study, July 27, 2026 Company announcement. Retatrutide half-life in people: Tetelbaun, Mullally and Frishman, Cardiology in Review, 2024 Journal article (review).